Profile data is unavailable for this security.
About the company
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
- Revenue in CHF (TTM)--
- Net income in CHF--
- Incorporated2022
- Employees23.85k
- LocationSandoz Group AGSuurstoffi 14ROTKREUZ 6343SwitzerlandCHE
- Websitehttps://www.sandoz.com/
More ▼
Mergers & acquisitions
| Acquired company | SDZ:SWX since announced | Transaction value |
|---|---|---|
| Coherus BioSciences Inc-CIMERLI Business | 41.22% | 170.00m |
Data delayed at least 15 minutes, as of Nov 21 2024 15:10 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hansoh Pharmaceutical Group Company Ltd | 1.48bn | 575.81m | 12.04bn | 9.10k | 21.17 | 3.53 | 19.28 | 8.15 | 0.8437 | 0.8437 | 2.16 | 5.06 | 0.3804 | 1.81 | 3.89 | 1,425,881.00 | 14.82 | 11.58 | 17.87 | 13.98 | 91.01 | 90.78 | 38.97 | 29.28 | 7.81 | -- | 0.0043 | 12.75 | 7.69 | 5.52 | 26.85 | 11.49 | -10.45 | -- |
| Incyte Corp | 3.60bn | 28.72m | 12.10bn | 2.52k | 507.68 | 4.32 | 113.35 | 3.36 | 0.14 | 0.14 | 18.79 | 16.45 | 0.715 | 4.23 | 5.76 | 1,614,842.00 | 0.5698 | 9.07 | 0.7404 | 11.02 | 93.37 | 94.97 | 0.7969 | 13.68 | 1.82 | -- | 0.01 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Cipla Ltd | 2.78bn | 469.02m | 12.46bn | 27.76k | 26.57 | 4.19 | 21.51 | 4.48 | 55.39 | 55.39 | 328.19 | 351.20 | 0.803 | 1.58 | 5.08 | 9,549,060.00 | 13.58 | 10.09 | 16.44 | 12.40 | 67.01 | 58.63 | 16.92 | 12.66 | 2.82 | 69.41 | 0.016 | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Royalty Pharma plc | 2.00bn | 1.01bn | 13.66bn | 89.00 | 10.25 | 2.26 | 21.53 | 6.82 | 2.56 | 2.56 | 3.80 | 11.63 | 0.1337 | -- | 72.15 | 25,460,710.00 | 10.11 | 9.57 | 13.30 | 12.42 | -- | -- | 75.64 | 67.80 | -- | -- | 0.4258 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Viatris Inc | 13.31bn | -781.01m | 13.86bn | 38.00k | -- | 0.7918 | 8.21 | 1.04 | -0.7389 | -0.7389 | 12.54 | 16.58 | 0.3219 | 2.23 | 4.94 | 396,013.20 | -1.89 | 0.0887 | -2.23 | 0.1061 | 42.49 | 40.29 | -5.87 | 0.2891 | 0.9615 | 2.37 | 0.443 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Astellas Pharma Inc | 10.08bn | 311.43m | 16.19bn | 14.75k | 51.70 | 1.84 | 11.35 | 1.61 | 30.42 | 30.42 | 986.34 | 854.61 | 0.5060 | 1.36 | 3.39 | 120,113,500.00 | 1.56 | 4.59 | 2.31 | 6.61 | 81.78 | 80.53 | 3.09 | 7.98 | 0.8623 | 15.32 | 0.3774 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
| Divi's Laboratories Ltd | 902.80m | 192.42m | 16.42bn | 17.50k | 85.34 | 11.42 | 70.50 | 18.19 | 69.14 | 69.14 | 324.44 | 516.71 | 0.5768 | 1.13 | 4.27 | 4,922,286.00 | 12.29 | 16.55 | 13.32 | 18.22 | 59.91 | 56.24 | 21.31 | 26.38 | 4.80 | -- | 0.0006 | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Teva Pharmaceutical Industries Ltd | 14.81bn | -876.81m | 16.91bn | 35.00k | -- | 3.16 | -- | 1.14 | -3.26 | -3.26 | 55.53 | 19.97 | 0.4001 | 2.05 | 4.90 | 1,788,132.00 | -2.99 | -3.14 | -4.34 | -4.29 | 51.01 | 48.14 | -7.46 | -9.87 | 0.6056 | 4.72 | 0.7483 | -- | 6.17 | -3.42 | 77.15 | -- | -4.17 | -- |
| Sandoz Group AG | -100.00bn | -100.00bn | 17.58bn | 23.85k | -- | 2.32 | -- | -- | -- | -- | -- | 17.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.7401 | -- | 0.3469 | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Bayer AG | 43.57bn | -820.42m | 17.90bn | 100.87k | -- | 0.6283 | 2.65 | 0.4108 | -0.8957 | -0.8957 | 47.58 | 31.11 | 0.417 | 1.49 | 4.49 | 468,688.30 | -0.7815 | -1.79 | -1.06 | -2.38 | 57.14 | 59.02 | -1.87 | -4.80 | 0.8059 | 2.97 | 0.5728 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 1.33bn | 375.76m | 18.19bn | 2.79k | 48.41 | 10.63 | -- | 13.67 | 5.10 | 5.10 | 18.08 | 23.24 | 0.6401 | 1.67 | 14.66 | 3,911,417.00 | 18.22 | 18.82 | 22.51 | 23.91 | 43.91 | 46.55 | 28.46 | 27.98 | 3.64 | -- | 0.0747 | 36.49 | 15.69 | 16.11 | 13.15 | 19.60 | 13.83 | 31.06 |
| Biogen Inc | 8.49bn | 1.43bn | 20.10bn | 7.57k | 14.10 | 1.38 | 10.04 | 2.37 | 11.07 | 11.07 | 65.83 | 112.90 | 0.34 | 0.8604 | 4.58 | 1,269,155.00 | 5.71 | 12.53 | 7.01 | 14.83 | 75.59 | 83.04 | 16.80 | 26.93 | 0.8039 | 4.89 | 0.2778 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
Data as of Nov 21 2024. Currency figures normalised to Sandoz Group AG's reporting currency: Swiss Franc CHF
19.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 05 Nov 2024 | 19.39m | 4.50% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 15.56m | 3.61% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 9.86m | 2.29% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 9.08m | 2.11% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 7.43m | 1.72% |
| Vontobel Asset Management AGas of 31 Oct 2024 | 4.76m | 1.11% |
| BlackRock Asset Management Deutschland AGas of 08 Nov 2024 | 4.03m | 0.94% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 4.03m | 0.94% |
| Geode Capital Management LLCas of 14 Nov 2024 | 3.99m | 0.93% |
| Boston Partners Global Investors, Inc.as of 07 Nov 2024 | 3.88m | 0.90% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
